6) In addition, once vaccine coverage levels exceed

6). In addition, once vaccine coverage levels exceed Wnt inhibitor 75%, the model predicts biennial patterns in rotavirus activity. This activity becomes increasingly more irregular and infrequent as coverage levels approach 100%. Whether vaccination immunizes only against a primary infection

or each dose immunizes against a corresponding natural infection, minimal differences in impact are seen between two or three dose vaccine schedules (Fig. 6). We found that our original model provided the best fit to the real data (Table 3). When duration of infectiousness, risk of becoming re-susceptible after each infection and proportion symptomatic at each infection were set at values greater than the original estimates, the predicted reduction in rotavirus

cases observed after the introduction of vaccination was less dramatic (Table 3). This is an important observation. In developing countries, child malnutrition may result in more symptomatic infections and poorer access to treatment may prolong the duration of infectiousness. This could result in the vaccine being less effective in reducing disease burden in these settings. We found that rotavirus disease patterns in England and Wales can be modelled well by a dynamic model of rotavirus transmission which takes into account the natural history of rotavirus infections. The model reproduces the regular seasonal pattern of rotavirus gastroenteritis and the age distribution of cases seen. Vaccination is expected to reduce the observed seasonal peak in rotavirus BIBW2992 supplier disease incidence and reduce the overall burden of disease. Model fit was obtained by using a cosine function for the seasonal variation in transmission. Understanding the driving forces underlying this seasonality remain elusive because it

is difficult to prove that common seasonal patterns between environmental exposures and disease incidence are not the result of some other underlying factor. However, low relative humidity and low temperature may explain short-term variations in rotavirus disease incidence [34] and [35]. Therefore it is plausible, that in part, these weather factors are responsible for seasonal patterns of rotavirus disease. Pitzer et al. [29] have developed a seasonally forced age-stratified transmission model for rotavirus which predicts rates below of rotavirus hospitalisations in the United States similar to those observed. The model differs to our model in a number of ways. Some of the differences in model assumptions may be due to the different types of data used in model fitting: Pitzer et al. fitted their model to hospitalization data for children <5 years, while in this study we fitted our model to laboratory surveillance reports for all age groups. Firstly, we included up to three potentially symptomatic re-infections, based on careful follow-up studies [15] and [18], whereas Pitzer et al.

However the confidence interval for the effect was very wide (95%

However the confidence interval for the effect was very wide (95% CI –22 to 30) so these data do not clearly rule out clinically important effects. Hung et al (2010) compared the effect of supervised abdominal muscle training and pelvic floor muscle training with unsupervised pelvic floor

training alone and found that abdominal muscle training was associated with a large absolute reduction in risk of self-reported lack of improvement of 30% (95% CI 11 to 47). However this study has several serious limitations including that, while participants in the control group were instructed in pelvic floor muscle training on one occasion, it appears that they did not receive ongoing supervision or feedback so the control intervention was not best practice. In Hormones antagonist addition,

more than half the participants had no leakage on a pad test at baseline. selleck compound Sriboonreung et al (2011) did not find any additional effect of adding abdominal training to pelvic floor muscle training on incontinence, and the confidence interval for this effect (mean difference in pad test result of −1 g, 95% CI −2 to 0) was sufficiently narrow to rule out the possibility that abdominal training conferred clinically significant benefits. In our opinion the evidence from randomised trials is currently ambivalent and does not provide strong support for the effectiveness of abdominal muscle training. Phase: Testing phase. Theory: All sphincters in the body work simultaneously, so exercising the ring muscles of the mouth, eyes, or nose will result in co-contraction and strengthening of the pelvic floor muscles ( Liebergall-Wischnitzer et al 2005). Non-randomised studies: Two research groups assessed whether contraction of the muscles around

the mouth and eyes results in co-contraction of the pelvic floor muscles ( Bø et al 2011, Resende et al 2011). Bø et al (2011) used perineal ultrasound to measure constriction of the levator hiatus and Resende et al (2011) used surface EMG to Carnitine dehydrogenase measure activation of the pelvic floor muscles during the Paula method. Neither research group found any co-contraction of the pelvic floor muscles during contraction of the mouth or eyes. Randomised trials: No trials compared the Paula method with no treatment. Two trials, one a pilot study of 59 women and the other a large trial of 245 women, have been conducted by one group of researchers ( Liebergall-Wischnitzer et al 2005, Liebergall-Wischnitzer et al 2009). In both trials, participants randomised to the group receiving Paula therapy attended up to 9 hours of individualised instruction and practised the Paula method including additional pelvic floor muscle contractions for up to 63 hours at home. Control group participants attended up to 3 hours of group classes and practised pelvic floor muscle exercise for up to 21 hours at home.

The above estimators were used for generating random realization

The above estimators were used for generating random realization of univariate data for respective conditions. The steps involved in the analysis are given as below: Step1: Generate a simulated

dataset using the estimated parameters from Equations (1) and (2) for all genes. Obtain moderated t-statistic values for the simulated dataset. Similarly, simulate 100 datasets and obtain moderated t-statistic values for the respective simulated dataset. Gene expression profiles of 89 Homo sapiens prostate samples were downloaded from a publicly available Cobimetinib database, ArrayExpress, of which, 34 were African–American prostate tumor samples, 35 were European–American prostate tumor samples, and 20 were cancer-free samples. In the present study, our interest was to compare 35 European–American with 34 African–American patients to detect the true significant genes that are involved in the prostate cancer progression. In literature, there are many sophisticated analytical and statistical approaches that were proposed to microarray normalization and differential

expression analysis. Akt inhibitor In the present analysis, the data was log transformed and normalized with median centering. The median absolute deviation was also performed on the datasets for uniformity of scale. The moderated t-statistic was applied on normalized dataset and for each simulated dataset, to detect true significant genes (see methods). The sorted observed

t-statistic values from normalized data and the sorted expected t- statistic values from simulated datasets are shown in Fig. 1. The set of significant genes identified at different thresholds (δ0) are given in Table 1. We obtained MDS classification of both tumor-groups of 34 African–American and 35 European–American samples (patients) second from each set of significant genes and correspondingly from the subset of significant genes. The classification of both tumor-groups was poor from all set of significant genes. The number of correctly classified and misclassified samples is also shown in Table 1. The samples GSE6956GSM160352, GSE6956GSM160358, GSE6956GSM160378 from African–American prostate tumors and GSE6956GSM160416, GSE6956GSM160379, and GSE6956GSM160365 from European–American prostate tumors were often misclassified. Hence, all these samples were eliminated from analysis and continued the analysis from step 1 to step 5 as mentioned in the methods. By excluding the above 6 samples, new moderated t-statistic values were obtained on normalized data and correspondingly for simulated datasets. The number of significant genes identified by choosing different thresholds is shown in Table 2. At a threshold of δ0 = 0.

However, this does not appear to provide a solid explanation for

However, this does not appear to provide a solid explanation for the lack of physiotherapy-led presentations

at national conferences identified in recent years. It buy GSK1120212 also fails to explain the imbalance between representation of physiotherapists and other health professionals in this arena. Physiotherapy organisations, academic institutions, and therapists could develop strategies to increase the engagement of physiotherapists in cardiology research. Some simple strategies could include the implementation of a mentoring system designed to link physiotherapists with established research backgrounds and clinicians working in the management or prevention of cardiac disease. Greater mentorship of postgraduate physiotherapy research on cardiac topics is also needed in physiotherapy schools. The establishment of more frequent communication between clinical and research physiotherapists, via bodies such as Cardiorespiratory Physiotherapy Australia, CSANZ, and ACRA may also inspire clinicians to consider research in this area. Funding and academic opportunities in the area of cardiovascular disease management are CCI-779 ic50 extensive. Exploration of these opportunities by physiotherapists would be fruitful for individual physiotherapists, the profession and, ultimately and most importantly, for patients. Research opportunities are widely available and physiotherapists

are ideally positioned to take a leadership role in the future evolution of cardiac management. In summary,

cardiac disease is a leading international health problem. Despite physiotherapists being ideally trained with relevant clinical experience there appears to be a general lack of engagement with cardiology research. The problem manifests across a range of domains including professional membership, active participation in national conferences, and publication of research in the area of cardiovascular disease. The expertise and capacity of physiotherapists coupled with extensive career opportunities in the area of cardiology research presents a range of opportunities for physiotherapists to explore. “
“Mechanical ventilation temporarily replaces or supports spontaneous breathing in critically ill patients in intensive care units. Weaning is the withdrawal of mechanical ventilation Olopatadine to re-establish spontaneous breathing. Patients are considered to have successfully weaned from ventilatory support when they can breathe on their own for at least 48 hours (Sprague and Hopkins, 2003). Weaning typically comprises 40–50% of the total duration of mechanical ventilation, with almost 70% of patients in intensive care weaning without difficulty on the first attempt (Boles et al 2007). Other patients have a more difficult or prolonged period of weaning, which is associated with a poorer prognosis (Vallverdu et al 1998, Esteban et al 1999).

i All animals survived to the end of the experiment (Table 2, Fi

i. All animals survived to the end of the experiment (Table 2, Fig. 2A). Mice immunised with VP2D1 + VP2D2, or VP2D1 + VP2D2 + VP5Δ1–100 of BTV-4, but challenged with BTV-8, showed signs of infection by day 3 p.i., and all had died by day 5 p.i (Fig. 2C). Ct values of 20.7–22.4, and virus titres

calculated by plaque assay were 7 × 103–2 × 104 pfu/ml on day 4 p.i. SB431542 In contrast, time of death was delayed (day 5–7 p.i. [P < 0.05]) by addition of VP7 to this immunisation regime (BTV-4 VP2D1 + VP2D2 + VP5Δ1–100 + VP7) ( Fig. 2C), with Ct values on day 5 p.i. of 22.4–23.7 (virus titres calculated by plaque assay: 3 × 103–7 × 103 pfu/ml, Fig. 2D). The two non-immunised control-groups, challenged with BTV-4(italy03), or BTV-8(BTV-8-28) were all positive by RT-PCR on day 3 p.i. and all died by day 5 p.i. (Fig. 2A and C) with Ct values 20.9–22.7. Virus was successfully isolated from these animals on both KC cells and BSR (BSR plaque assay titres: 5 × 103–3 × 104 pfu/ml (Fig. 2B and D)). Animals in the group immunised with VP5Δ1–100 were not challenged because initial studies with Balb/c mice

showed that sera of mice immunised with VP5Δ1–100 only, did not neutralise virus infectivity. All animals in the groups immunised with VP7 only, died by day 5 p.i. with levels of BTV-specific RNA in blood similar to selleck screening library non-immunised mice (BSR plaque assay titres: 4 × 103–2.7 × 104 pfu/ml). This suggests that increased survival times of mice immunised with VP2D1 + VP2D2 + VP5Δ1–100 + VP7 is not due to VP7 alone, but may be an effect of combining these different proteins. Several inactivated mono- and multivalent vaccines for BTV serotypes 1, 2, 4 or 8, have been authorised via the European Medicines Agency for use in ruminants, particularly cattle and sheep [41] and [42]. These relatively un-purified vaccine antigens raise antibodies to all virus structural and non-structural proteins, making it Calpain impossible to distinguish infected from vaccinated animals (DIVA) by serological

assays. Previous studies exploring recombinant-expressed BTV structural proteins as subunit-vaccine candidates have evaluated crude lysates of recombinant-baculovirus-infected insect cells expressing BTV VP2 and VP5 [43], [44] and [45]. Immunisation of sheep with these proteins, protected the animals and raised significant NAb titres (up to 2.408), with transient or undetectable viraemia after a subsequent homologous-BTV challenge [43]. Recently, it was shown that baculovirus-expressed and purified VP2 induced neutralising antibodies [45] and is stable at +4 °C as well as −80 °C for almost 2 years [46]. Immunisation with virus-like particles (VLPs) containing capsid-proteins (VP3, VP7, VP2 and VP5) also protected sheep and raised NAbs (titres of upto 2.

altilis, 23 and A communis collected from Indonesia 24 The comp

altilis, 23 and A. communis collected from Indonesia. 24 The compound

total synthesis has also been reported. 25 The compound, 1 was shown to be a potent inhibitor of cathepsin K 25 at an IC50 value of 170 nM. The dendrite elongation inhibition activity of the crude extract, fractions and isolated compound were evaluated by cell culture method by visual observation, estimating the length of dendrites.1 The assay method is most precise and reliable. The melanocyte cells, B16F10 were used for the present study. The cells were cultured in DMEM in the presence of 5% carbon dioxide, 10% serum, pencillin (100 μg/ml), streptomycin (50 μg/ml), amphotericin B (2.5 μg/ml). 1 × 105 cells were seeded in 60 mm cell KU-57788 in vivo culture dish and were incubated with and without the test material for 24 h. After 24 h selleckchem incubation, the cells were examined under an inverted microscope against negative control. The dendrite length was measured and calculated the % inhibition of the cell length (Table 1). The ethyl acetate

fraction and crude methanol extract were shown good dendrite elongation inhibition at 50 μg/ml and isolated compound was showed good activity at same concentration. The present study on the leaves of A. altilis resulted in the isolation of one known compound, 1 ( Fig. 1). Its structure has been identified on the basis of spectroscopic data and comparison with the literature data. The crude methanolic old extract, its fractions and isolated compound were studied for dendrite elongation property and the compound has shown good dendrite elongation inhibition. All authors have none to declare. The authors are thankful to Mr.C.K. Ranganathan, CMD of CavinKare Pvt. Ltd., Chennai for his constant encouragement and providing necessary facilities. “
“Duloxetine is itself a moderate inhibitor of CYP2D6 and therefore may interact with drugs that are extensively metabolized by CYP2D6.

This may lead to clinically significant increases in plasma levels of CYP2D6 substrates that have a narrow therapeutic index (such as Metoprolol, perhexiline, phenothiazines, or flecainide). CYP2D6 is responsible for the metabolism of drugs commonly used to treat various medical conditions; some examples include anti-estrogen, Tamoxifen,1 atypical opioid tramadol,2 anti-arrhythmic amiodarone3 and cyclooxygenase-2 inhibitor celecoxib.4 It is important, therefore, that physicians are aware of the potential for clinically relevant interactions when prescribing antidepressants. Since diabetic patients are vulnerable to diabetic complications like diabetic cardiovascular disorders and diabetic neuropathy, it is very likely that Duloxetine and Metoprolol are concomitantly administered for diabetic neuropathic pain and diabetic cardiovascular disorders respectively.

Participants: The mean age of participants across the studies ran

Participants: The mean age of participants across the studies ranged from 50 to 74 years. The mean time after stroke ranged from 1.6 to 27 months, and one study did not report this information. Participants were recruited from people living in the community in 55% of the trials. Intervention: In all studies, the experimental group received treadmill training without body weight support. Participants undertook training for 25 to 40 min, 3–5/wk,

for 2.5 to 26wk. The control group received no intervention (three studies), a non-walking intervention (four studies), or overground walking (three studies). Outcome measures: Walking speed was measured JNJ-26481585 concentration using the 10-m Walk Test (eight studies) and results were converted to m/s. Walking distance was measured using the 6-min Walk Test (seven studies) and results were converted to m. Walking speed: The immediate effect of treadmill training versus no intervention or a non-walking intervention on walking speed was examined by pooling data from seven studies ( Ada et al 2003, Eich et al 2004, Weng et al 2006, Ivey et al 2011, Kuys et al 2011, Olawale et al 2011, Ada et al 2013) involving 275 participants. Treadmill training increased walking speed 0.14 m/s (95% CI 0.09 to 0.19) more than no intervention/non-walking intervention ( Figure 2a, see Figure 3a on the eAddenda for the detailed forest plot). The effect of treadmill

training beyond the intervention Selleck Epigenetics Compound Library period compared with no intervention/non-walking intervention on walking speed was examined by pooling data from four studies ( Ada et al 2003, Eich et al 2004,

Kuys et CYTH4 al 2011, Ada et al 2013) involving 167 participants. Treadmill training increased walking speed 0.12 m/s (95% CI 0.08 to 0.17) more than no intervention/ non-walking intervention ( Figure 2b, see Figure 3b on the eAddenda for the detailed forest plot). The immediate effect of treadmill versus overground training on walking speed was examined by pooling data from three studies (Pohl et al 2002, Langhammer and Stanghelle 2010, Olawale et al 2011) involving 119 participants. There was no significant difference in walking speed between treadmill training and overground training (MD 0.05 m/s, 95% CI −0.12 to 0.21) (Figure 4, see Figure 5 on the eAddenda for a detailed forest plot). No studies measured the effect of treadmill training versus overground walking on walking speed beyond the intervention period. Walking distance: The immediate effect of treadmill training versus no intervention or a non-walking intervention on walking distance was examined by pooling data from six studies ( Ada et al 2003, Eich et al 2004, Ivey et al 2011, Kuys et al 2011, Olawale et al 2011, Ada et al 2013) involving 249 participants. Treadmill training increased walking distance 40 m (95% CI 27 to 53) more than no intervention/non-walking intervention ( Figure 6a, see Figure 7a on the eAddenda for the detailed forest plot).

Liver and kidney samples were homogenized in ice-cold phosphate-b

Liver and kidney samples were homogenized in ice-cold phosphate-buffered saline supplemented with protease inhibitor cocktail (1:30 dilution; Sigma–Aldrich, St. Louis, MO, USA). After centrifugation

Bioactive Compound Library solubility dmso at 9100g for 30 min at 4 °C, the supernatants were collected. The extraction efficiency was approximately 80% for kidney and liver samples, and >90% for blood samples. Partisil® RP TLC plate (KC-18 Silica Gel 60 Å; Whatman Inc., Clifton, NJ, USA) as the stationary phase was loaded with 2–2.5 μL of plasma, urine, tissue supernatant, injectate, and undiluted 64Cu-cyclam-RAFT-c(-RGDfK-)4 or 64Cu solution, and developed in the mobile phase of methanol/10% ammonium acetate (70/30 v/v). The radioactive components separated on the plate—corresponding to 64Cu-cyclam-RAFT-c(-RGDfK-)4, its radioactive metabolites, and free 64Cu—were exposed to an imaging plate, and scanned using a bioimaging analyzer as previously described [6]. The proteins were then visualized by exposure to iodine vapor. Samples from the same mouse and the injectate as the internal standard were analyzed on one TLC plate, with several samples, including urine and

the injectate, being Sorafenib mouse appropriately diluted in NS. Quantitative data were presented as mean ± SD and compared using one-way ANOVA followed by Bonferroni test for multiple comparisons. P values < 0.05 were considered statistically significant. Table 1 shows the effect of various doses of GF on the biodistribution of 64Cu-cyclam-RAFT-c(-RGDfK-)4

in normal mice at 3 h p.i. Renal radioactivity was significantly reduced by 35.3% in the presence of 80 mg/kg GF; however, increased doses of 120 and 200 mg/kg did not lead to further reductions. Blood radioactivity (as low as 0.03 ± 0.01%ID/g) was not significantly influenced by GF at any of the doses tested. In other organs, co-injection with GF tended to result in a slight increase in radioactivity, independent of the doses used. Based on these results, the dose of 80 mg/kg was selected for all subsequent studies. Fig. 2 shows the effect of Lys and the combined effect of GF and Lys on the biodistribution of 64Cu-cyclam-RAFT-c(-RGDfK-)4 in normal mice at 3 and 24 h p.i. l-lysine alone did not affect Bay 11-7085 the biodistribution of 64Cu-cyclam-RAFT-c(-RGDfK-)4 at either 3 or 24 h p.i in any of the organs examined, except in the stomach. When Lys was added to GF, the 31.5% (3 h p.i.) and 26.6% reductions (24 h p.i.) in renal radioactivity caused by GF alone were increased to 36.1% (P > 0.05) and 37.9% reductions (P = 0.03), respectively. Interestingly, unlike GF alone, GF + Lys did not significantly affect accumulation of radioactivity in other organs. The effect of GF ± Lys was examined in mice bearing αVβ3-positive U87MG tumors (Table 2). The tumor uptake of 64Cu-cyclam-RAFT-c(-RGDfK-)4 was slightly increased in the presence of GF ± Lys.

In addition, we are also aware of the need to determine whether t

In addition, we are also aware of the need to determine whether these toxins are able to interfere with the CNS via the olfactory nerve. Similar studies with LT and CT have shown that nasal application can result in potential toxicity to the CNS via binding of the toxin to bind olfactory lobes via GM1 gangliosides. Whilst it is possible for this to occur, PLY is more readily manipulated genetically than LT and CT holotoxins and therefore provides opportunities

to alter the protein to maximise the adjuvant activity whilst limiting the potential for CNS involvement. This does HA-1077 cost not detract from other efforts elsewhere to harness the activity of the LT and CT proteins, by the generation of chimeric proteins encoding either the CT-A (LT-A) or CT-B (LT-B) domains. In fact, a PsaA-CT-B fusion was found to stimulate PsaA responses in mice [28]. In addition, ongoing studies have indicated that other routes of immunisation may also Bosutinib provide as significant a response as those generated via the i.n. route described here (data not shown). It is hoped further study and refinement of PLY as a delivery system will provide an effective platform for the generation of several new, effective and safe mucosal vaccines of the future. This work was supported by BBSRC scholarship to Kirsty Ross and a Glasgow University Scholarship to Graeme Cowan.

GRD research group is supported by a Wellcome Trust grant 080860. Work in the Mitchell group is supported enough by Wellcome Trust, European Union and PATH. “
“It is a challenge of modern vaccine development to achieve a robust immune response against weakly immunogenic targets such as a subunit vaccines [1] and [2]. Such a result can be achieved by inclusion of an adjuvant, which augments the immune response to codelivered antigen [3]. New adjuvants which are safe and potent are needed for the next generation of vaccines. Furthermore, induction of mucosal

immunity by an adjuvant should improve protection against pathogens which enter the body by a mucosal route [4] and [5]. Although mucosal immunity has traditionally been generated in response to a mucosally delivered antigen, it is also possible to generate a mucosal immune response by parenteral delivery of antigen under the right conditions [6], [7], [8], [9], [10], [11], [12], [13], [14], [15] and [16], including codelivery of replicons from the Venezuelan equine encephalitis virus (VEE) [17]. VEE is a positive sense alphavirus whose RNA genome encodes four non-structural replicase proteins (nsPs), followed by an internal promoter (26S) which controls the transcription of a subgenomic mRNA encoding the virion structural proteins. The adjuvant qualities of this virus were first identified 40 years ago, when it was shown that VEE virus inoculation enhanced the immune response to antigen [18] and [19].

5 and 6 Bark is the most utilized plant part

and is used

5 and 6 Bark is the most utilized plant part

and is used as a major constituent for the preparation of various formulations and most widely available is Ashokarista. Since the medicinal properties of S. asoca are being commercially exploited throughout the world to treat gynecological and other disorders. As all the parts have different pharmacological properties, in turn, all the different plant parts will have different chemical constitution. To strengthen this Transmembrane Transporters activator faith, it is necessary to develop discriminative analytical models for the authentication and quality control of raw as well as processed herbal drugs and to identify substitutes/adulterants. Ultra performance liquid chromatography [UPLC] coupled to quadrupole-time-of-flight mass spectrometer [Q-TOF-MS] is excellent technique to analyze multi-components Ipatasertib order in the complex herbal extracts7 and 8 due to separation of compounds by UPLC along with accurate mass measurement, high resolution and ion separation due to Time of Flight.8 Rapid data mining procedures and aligning algorithms tools been used to process huge raw data generated from metabolome analyzes.9 These processed data have been used successfully in various pharmaco-physiological studies such as disease diagnostics,

drug discovery10 and human nutritional science.10, 11 and 12 Therefore, in the present study, UPLC Q-TOF-MS has been used to generate MS/MS data of various samples of Ashokarista and S. asoca. Non-targeted MS/MS data was processed for principal component analysis [PCA] and partial least square discriminant analysis [PLS-DA] for discrimination of Terminal deoxynucleotidyl transferase samples and analysis of most abundant metabolites

which can be used as biomarkers. Standard compounds lidocaine, D-camphor, 5-7-isoflavone, catechin and solvents i.e. acetonitrile, formic acid and water of LCMS grade were purchased from Sigma–Aldrich. Three samples of each i.e. bark, regenerated bark, leaves and flowers of S. asoca were collected in February, 2012 from Botanical Garden of NRIBAS, CCRAS, [Dept of AYUSH], Nehru Garden, Kothrud, Pune. The collected plant materials were identified and voucher specimens [No. 207] kept at the medicinal plant museum of the Institute. The Ashokarista formulations of Baidyanath Pvt Ltd [Batch No 110085, mfg April 2011] and Dabur Pvt Ltd [Batch No BD1049, mfg Sept 2010] were purchased from authorized medical stores. Fresh plant materials [20 g each] were extracted overnight [at 25 and 70 °C] with deionized water [Direct-Q, Millipore] [1:1 w/v]. Extraction steps were repeated three times to ensure complete recovery of metabolites. Samples were filtered through 0.22 μ filters [Hi-media], lyophilized using a lyophilizer [Freezone 4.5 Labconco] and stored at −80 °C till further use. The plant extracts were reconstituted in LC/MS grade water [5.0 mg/ml] for further analytical studies.